https://www.selleckchem.com/pr....oducts/tucidinostat-
important preliminary estimates of the impact of this mHealth technology for patients initiating buprenorphine, as well as the feasibility of study procedures, thus paving the way for further research to assess feasibility and generate preliminary data for design of a future Phase III trial. Trial Registration ClinicalTrails.gov, NCT03779997, Registered on December 19, 2018. Video DOT delivered through mHealth technology platform offers possibility of improving patients' buprenorphine adherence by providing additional str
Like
Comment
Share
